Ascelia Pharma Provides Orviglance® Update Following FDA Type A Meeting

Ascelia Pharma announced it has received the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) for its Orviglance® New Drug Application (NDA). The FDA acknowledged that Orviglance addresses a significant unmet medical need, has no major safety concerns, and existing clinical studies provide evidence supporting its technical performance as a T1-weighted MRI contrast enhancement agent. While the FDA maintains that approval would require additional clinical evidence, it also suggested that a prospective analysis of images from the Phase 3 SPARKLE study using a different primary endpoint could potentially generate the necessary evidence. Ascelia Pharma does not plan to conduct another clinical study and will evaluate the most efficient regulatory path forward in the U.S. based on the existing SPARKLE dataset, while continuing European regulatory activities and partnering efforts.